Search
Eteplirsen
go.drugbank.com/drugs/DB06014ApprovedInvestigationalEteplirsen was first approved by the FDA in September 2016 for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene, which codes for dystrophin, that … Eteplirsen directly works on the DMD gene to promote dystrophin production. Eteplirsen was the first treatment for DMD approved by the FDA.[A244925]
Categories: Compounds used in a research, industrial, or household settingSynonyms: N-dimethylphosphonamidate) RNA, dimethylamino)](2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a→5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G),5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,Turpentine
go.drugbank.com/drugs/DB11120ApprovedIt is used as a solvent and base material in organic synthesis reactions. … Turpentine is composed of terpenes, mainly the monoterpenes alpha-pinene and beta-pinene with lesser amounts of carene, camphene, dipentene, and terpinolene.
Mixtures: NORAVER U, Cal Mo Dol OntCategories: Compounds used in a research, industrial, or household settingSparsentan
go.drugbank.com/drugs/DB12548ApprovedInvestigational>A</sub>R and 0.8 nM for AT<sub>1</sub>R). … Sparsentan is a dual antagonist of the endothelin type A receptor (ET<sub>A</sub>R) and the angiotensin II (Ang II) type 1 receptor (AT<sub>1</sub>R) with a similar affinity for both (9.3 nM for ET<sub
Categories: Agents Acting on the Renin-Angiotensin System, Angiotensin II receptor antagonistsHydroflumethiazide
go.drugbank.com/drugs/DB00774ApprovedWithdrawnA thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)
Tenofovir alafenamide
go.drugbank.com/drugs/DB09299ApprovedInvestigational[T239] Tenofovir alafenamide is an alanine ester form characterized for presenting low systemic levels but high intracellular concentration. … Tenofovir alafenamide is a novel [tenofovir] prodrug developed in order to improve renal safety when compared to the counterpart [tenofovir disoproxil].
Categories: Antivirals used in combination for the treatment of HIV infections, Antivirals for Systemic UseMilnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalFurthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia [F3925], although other regional regulatory authorities like the EMA, among others, have not … Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment
Categories: Analgesics, Non-Narcotic, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTamoxifen
go.drugbank.com/drugs/DB00675ApprovedInvestigational[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments. … [L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole].
Synonyms: (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine, (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamineAminobenzoic acid
go.drugbank.com/drugs/DB02362ApprovedWithdrawnIt used to be common in sunscreening agents until found to also be a sensitizer. The potassium salt is used therapeutically in fibrotic skin disorders.
Categories: Protectives Against UV-Radiation for Topical Use, Protectives Against UV-RadiationAlpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalnegative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. … To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests.
Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitorsZenocutuzumab
go.drugbank.com/drugs/DB15559ApprovedInvestigational[L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma. … [A264833] On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab for the treatment of non-small cell lung cancer and pancreatic adenocarcinoma.